Battelle has received a Drug Enforcement Administration license that allows the company’s Centers for Substance Use Research to expand its current program.
The company said Tuesday it aims to study the behavioral and physical effects of marijuana on human subjects through the Schedule I Researcher license.
DEA classify Schedule I substances as drugs with no proven or accepted medical use and have a high potential for abuse.
The National Institute on Drug Abuse’s Drug Supply Program will provide research-grade marijuana for Battelle’s study that will involve U.S. adults who currently use the substance.
Battelle’s research team is made-up of professionals who specialize in behavioral science, analytical and physical chemistry, pharmacology, psychology and toxicology.